CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.
about
Novel agents for chronic lymphocytic leukemiaThe role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemiaAnti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma TherapyBlinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaNovel agents and biomarkers for acute lymphoid leukemiaBlinatumomab: enlisting serial killer T-cells in the war against hematologic malignanciesAntigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomabDevelopment of Novel Immunotherapies for Multiple MyelomaSecond-generation inhibitors of Bruton tyrosine kinaseMitochondrial structure alteration in human prostate cancer cells upon initial interaction with a chemopreventive agent phenethyl isothiocyanateSynergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cellsSTAT inhibitors for cancer therapy.Clinical Pharmacology and Translational Aspects of Bispecific AntibodiesConstruction and expression of a novel anti-CD14 human-mouse chimeric antibody Hm2F9Comparison of mesenchymal stem cell markers in multiple human adult stem cellsCritical role of SHP2 (PTPN11) signaling in germinal center-derived lymphoma.Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.Cloning and Expression of CD19, a Human B-Cell Marker in NIH-3T3 Cell Line.Nephrotoxicity of recent anti-cancer agents.Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma.Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Differential gene expression profiles of PPP2R5C-siRNA-treated malignant T cells.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Ibrutinib for B cell malignancies.Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia.Generation of Monoclonal Antibodies against Immunoglobulin Proteins of the Domestic Ferret (Mustela putorius furo).Ibrutinib and novel BTK inhibitors in clinical development.CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia.Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALLBlinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.Engineering of synthetic gene circuits for (re-)balancing physiological processes in chronic diseases.CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-Immunophenotypic challenges in diagnosis and monitoring: A study of three cases.Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches.Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.Diagnosis and treatment of CD20 negative B cell lymphomas.Identification of an Atypical Enzootic Bovine Leukosis in Japan by Using a Novel Classification of Bovine Leukemia Based on Immunophenotypic Analysis.
P2860
Q21198858-41552BF2-24E8-4BAB-AF1D-1B03EF4C8F2AQ26744280-8DD132CD-845A-46DB-84E0-4353EE658B0FQ26775363-61C09F37-7DDE-419A-B4BA-5F8DE2DF51FAQ26785828-0A1BF0BC-993B-492F-BC66-C4EA5F48985FQ26829775-A45F8A25-0E4F-41C6-88D2-0A4E584099C8Q26865838-B399EB15-C1C2-4771-9DED-FFF471BF609AQ27013710-7C5CBECD-2477-4B4B-8638-B6D89F9DE823Q28066890-0C711255-4396-423B-8847-8B56CBC118DFQ28076118-1A0723B0-C60C-424E-942F-700847860656Q28384383-8FEB8B90-CF83-471C-979E-918738FE7873Q28397373-E318A728-F448-4555-8C0E-BB148E17396BQ33644206-975D88BB-C7FA-4751-8E53-ADDA7D12334CQ33648086-979323D6-9BA6-4D02-8500-FF92C371E1BEQ34088284-5DDAFF1F-021C-496E-8A1B-0C35D3CF85ABQ34599681-C92193CE-A957-4163-BA21-F7E6FB4317EAQ34649044-8BFEB660-50D1-48F6-9CB3-4831F23724A9Q34721223-F64AB532-C083-459E-80DC-09A0ED28E980Q35307091-AE788307-7ED0-4274-BDD4-69E8B1ED86F8Q35310741-A0754310-5B7E-40BA-BA94-E09392D0AAE0Q36546004-3BB15739-EDB4-43D1-88BF-B7D205203DD3Q36940760-D3C17446-0D99-4BA1-8849-E2AB8C88CAB0Q36979140-9CD7BE51-924C-4FE3-9A30-4402AE56FC42Q37202568-C3072D32-3B31-4B8B-966A-AD2A202490E0Q37350230-2F67625B-3C61-4D9D-91D0-069923D2DADCQ37555418-0E6C0C70-F0C1-4642-AFF7-B8E7C8CB559CQ37645126-D1D6461C-575F-4752-9408-D0032765D6AEQ37670852-0124810F-88C2-48E7-B789-FD14E26DD87EQ38130010-E2AD5ED8-A021-44B8-B160-543EF4CC6971Q38164792-A20B4E77-469A-4993-8983-544CC9478272Q38260357-06B7CB51-2BBC-4A01-979B-CF3ECB4599DBQ38371387-8D86BAF6-F5B3-48D6-9F55-57248728058FQ38376489-8996749B-CCE0-4A2F-9529-0557D3536E1BQ38799449-AB19AD92-27F6-4E6D-8AAA-867F31BF6D7AQ38876131-A8204CF3-B8D1-495F-9A18-A1FD0E7C8B6FQ38889598-BEFE782A-54F1-4C94-B069-5AB46262915BQ38989496-095E9F73-632C-4915-9738-B82EE081D50EQ39100049-8BEF09B6-2F84-4940-8E5C-8E16FE105B33Q39128240-58E5941F-3255-48B9-9A81-D3C9643E4E8DQ39132786-37E12794-248B-40B0-8ED2-8FB678B4FC4CQ40142063-5E962BD7-2FDF-4295-B493-75A207E8B1F9
P2860
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.
@en
type
label
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.
@en
prefLabel
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.
@en
P2093
P2860
P356
P1476
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.
@en
P2093
Delong Liu
Guoqing Wei
Kemeng Wang
P2860
P2888
P356
10.1186/2162-3619-1-36
P577
2012-11-29T00:00:00Z
P5875
P6179
1030655151